|Bid||153.36 x 1000|
|Ask||153.51 x 900|
|Day's Range||152.95 - 155.29|
|52 Week Range||96.14 - 155.30|
|Beta (3Y Monthly)||1.23|
|PE Ratio (TTM)||43.84|
|Earnings Date||Jul 31, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||163.00|
EVP & CIO of Masimo Corp (30-Year Financial, Insider Trades) Yongsam Lee (insider trades) sold 12,500 shares of MASI on 07/15/2019 at an average price of $151.82 a share. Continue reading...
Masimo announced today that in a study recently published in the Journal of Clinical Monitoring and Computing, researchers investigated the ability of Masimo ORi™ to serve as a noninvasive indicator of the arterial partial pressure of oxygen during general anesthesia, to help avoid hyperoxia.1 ORi is an index of oxygenation in the moderate hyperoxic region .
Masimo is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions.
CEO and Chairman of the Board of Masimo Corp (NASDAQ:MASI) Joe E Kiani sold 100,000 shares of MASI on 07/01/2019 at an average price of $150.14 a share.
If you've ever gotten shaken out of a long-term winner like Apple stock, here's how to get rich by avoiding mental mistakes.
Today, we'll introduce the concept of the P/E ratio for those who are learning about investing. We'll show how you can...
The Healthcare and Wealthcare basket gets investors a diversified and pretty darn safe entry to what can be a very volatile market.
Masimo announced today that in a study recently published in Anesthesia & Analgesia, researchers investigated the incidence of isoelectric electroencephalogram events in infants and young children undergoing scheduled surgery requiring general anesthesia.1 To assess the prevalence of these events, the researchers used Masimo SedLine® brain function monitoring, available on the Root® Patient Monitoring ...
Baxter (BAX) expects its bottom line to rise in the second quarter of 2019, courtesy to Renal Care and Clinical Nutrition businesses.
Masimo (MASI) gets FDA nod for its O3 Regional Oximetry that will help in delivering accurate measurement with respect to neonatal patients.
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Masimo Corp NASDAQ/NGS:MASIView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for MASI with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting MASI. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding MASI totaled $161 million. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Masimo announced today that O3® Regional Oximetry has received FDA clearance for use on neonatal and infant patients . O3 may help clinicians monitor cerebral oxygenation in situations in which peripheral pulse oximetry alone may not be fully indicative of the oxygen in the brain.
How do we determine whether Masimo Corporation (NASDAQ:MASI) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. They may not always be right (no one is), but data shows that […]